stoxline Quote Chart Rank Option Currency Glossary
Rhythm Pharmaceuticals, Inc. (RYTM)
45.16  1.1 (2.5%)    02-23 16:00
Open: 44.03
High: 45.7464
Volume: 512,388
Pre. Close: 44.06
Low: 43.75
Market Cap: 2,669(M)
Technical analysis
2024-02-23 4:39:17 PM
Short term     
Mid term     
Targets 6-month :  55.52 1-year :  61.4
Resists First :  47.53 Second :  52.56
Pivot price 48.21
Supports First :  39.4 Second :  32.78
MAs MA(5) :  47.27 MA(20) :  47.43
MA(100) :  36.58 MA(250) :  26.72
MACD MACD :  0.9 Signal :  1.5
%K %D K(14,3) :  28.1 D(3) :  43.9
RSI RSI(14): 46.6
52-week High :  52.56 Low :  15.5
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ RYTM ] has closed above bottom band by 17.2%. Bollinger Bands are 7.3% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 45.85 - 46.16 46.16 - 46.43
Low: 43.01 - 43.39 43.39 - 43.74
Close: 44.56 - 45.17 45.17 - 45.72
Company Description

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is also developing setmelanotide, which is in Phase II clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, Smith-Magenis syndrome obesity, POMC epigenetic disorders, and other MC4R disorders. Rhythm Pharmaceuticals, Inc. has a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Headline News

Mon, 26 Feb 2024
Clearbridge Investments LLC Purchases Shares of 182825 Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - AmericanBankingNEWS

Mon, 26 Feb 2024
Citigroup Inc. Sells 18921 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - AmericanBankingNEWS

Sun, 25 Feb 2024
Primecap Management Co. CA Cuts Position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - MarketBeat

Sat, 24 Feb 2024
Rhythm Pharmaceuticals Full Year 2023 Earnings: Revenues Disappoint - Simply Wall St

Fri, 23 Feb 2024
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Q4 2023 Earnings Call Transcript - Insider Monkey

Fri, 23 Feb 2024
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Q4 2023 Earnings Call Transcript - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 59 (M)
Shares Float 46 (M)
Held by Insiders 0.3 (%)
Held by Institutions 113.6 (%)
Shares Short 8,860 (K)
Shares Short P.Month 8,140 (K)
Stock Financials
EPS -3.25
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 3.33
Profit Margin -299.4 %
Operating Margin -195.4 %
Return on Assets (ttm) -31.2 %
Return on Equity (ttm) -77.6 %
Qtrly Rev. Growth 425.2 %
Gross Profit (p.s.) 0
Sales Per Share 1.04
EBITDA (p.s.) -3.11
Qtrly Earnings Growth 0 %
Operating Cash Flow -141 (M)
Levered Free Cash Flow -92 (M)
Stock Valuations
PE Ratio -13.94
PEG Ratio 1.7
Price to Book value 13.52
Price to Sales 43.06
Price to Cash Flow -18.96
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android